Skip to main content

Table 4 Prevalence of resistance mutations in 2010 among those typed and estimated prevalence in the population

From: Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal

 

Study samples

Prevalence in population$

 
 

Control area

SMC area

Control area

SMC area

Prevalence ratio^

p-value

SMC/ non SMC (95% CI)

Prevalence of parasitaemia:

6/216

21/882

2.47

1.76

0.71 (0.23, 2.20)

0.55

Prevalence of mutations

      

dhfr triple (51, 59, 108)

4/4

19/21

2.78

2.15

0.78 (0.30, 1.98)

0.60

dhps-437

4/4

18/21

2.78

2.04

0.74 (0.28, 1.90)

0.52

SP resistant mutant (dhfr triple + dhps 437)

4/4

18/21

2.78

2.04

0.74 (0.28, 1.90)

0.52

crt CVIET mutation

2/5

8/22

1.11

0.87

0.78 (0.15, 4.09)

0.77

mdr 86Y

0/5

12/22

0

1.30

-

-

mdr 184F

2/5

15/22

1.11

1.62

1.46 (0.27, 8.05)

0.66

AQ resistant mutant (mdr 86Y + crt CVIET)

0/5

5/22

0

0.54

-

-

SP resistant & AQ resistant

0/4

5/21

0

0.57

-

-

  1. ^ Prevalence ratios accounting for survey design. $For genotypes, prevalence among population is estimated as the product of 1) the probability of a resistant genotype among the typed samples and 2) the probability positive among samples with a definitive result (positive or negative) for asexual stage parasitaemia. Standard errors estimated by the delta method as described in the methods section.